LONDON – Anergis SA raised CHF18 million (US$19.6 million) in a Series A round to fund the development of allergy vaccines based on synthetic versions of natural allergens, which it said will be able to induce tolerance more quickly than is the case with de-sensitizing through the long-term administration of natural allergens.